Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.
Atara Biotherapeutics has become the first biotech to win regulatory approval for a T-cell therapy based on donated cells, rather than relying on cells harvested from patients and processed
Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.
Atara Biotherapeutics' cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according to the EMA's human med
Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.
